CRBP CORBUS PHARMACEUTICA

6.70
+0  (2%)
Previous Close 6.60
Open 6.70
Price To book 33.00
Market Cap 326.30M
Shares 48,701,000
Volume 560,512
Short Ratio 4.72
Av. Daily Volume 1,246,430

SEC filingsSee all SEC filings

  1. 8-K - Current report 17768869
  2. DEF 14A - Other definitive proxy statements 17753970
  3. PRE 14A - Other preliminary proxy statements 17730638
  4. 8-K - Current report 17723759
  5. 8-K - Current report 17685906

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 30, 2017 - primary endpoint met but some concerns regarding efficacy.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 trial to be initiated 2Q 2017.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 2 data due 3Q 2017.
Anabasum (Resunab)
Dermatomyositis
Phase 2 data released November 14, 2016. Phase 3 trial to be initiated 4Q 2017.
Anabasum (Resunab)
Systemic Sclerosis

Latest News

  1. Read This Before You Buy Biotech Stocks
  2. Top 4 Medicinal Marijuana Stocks to Watch for 2017
  3. Yikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016
  4. Big Investors Backing A Marijuana Boom In 2017
  5. Did Corbus Investors Get Thrown Off by a Red Herring?
  6. 5 Drug-Developing Marijuana Stocks You Need to Know
  7. What's Next for Corbus Pharmaceuticals After Its Controversial Cystic Fibrosis Results?
  8. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corbus Pharmaceuticals Holdings, Inc.
  9. Corbus Gets FDA Green Light for Phase 3 Drug Study
  10. Corbus says anti-inflammatory drug will enter late-stage trial this year
  11. Corbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
  12. Why The Corbus Pharmaceuticals Holdings Inc (CRBP) Cystic Fibrosis Results Are Very Positive
  13. Play the Marijuana Rush as First Marijuana-Focused ETF Launches
  14. Blog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA, BUNAVIL, and ONSOLIS
  15. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals
  16. Corbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : March 31, 2017
  17. Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients
  18. Why "Positive" Data Knocked Down Corbus Pharmaceuticals Holdings Inc Today
  19. Corbus Pharma Add-on Drug Clears Mid-Stage Study
  20. Blog Coverage Acorda Reported Long-term Safety Data